Positions: University of Cambridge Professor of Experimental Haematology, Honorary Faculty member Wellcome Trust Sanger Institute, Honorary NHSBT Consultant in Haematology.
Email: Julie Anderson (PA to Prof Ouwehand) Ouwehandemail@example.com
Tel.: +44 (0)1223 588183 (NHSBT feature net 48183)
The NHS Blood and Transplant (NHSBT) research group, led by Professor Willem Ouwehand, is embedded in the Department of Haematology at the University of Cambridge and collaborates with the Wellcome Trust Sanger Institute (WTSI) and the European Bioinformatics Institute (EBI). The group’s program of research in megakaryocyte and platelet biology and genomics is one of the largest in Europe and focuses primarily on the relationship between sequence variation in genes transcribed in megakaryocytes and the volume, count and function of platelets. A multidisciplinary team of 60 with skills in molecular biology, protein biochemistry, antibody engineering, genomics, and bioinformatics work together on different aspects of human platelets.
Platelet Biology & Genomics
Platelets are the second most abundant cell in the blood and are produced by fragmentation of megakaryocytes that reside in the bone marrow. Platelets are pivotal to maintain integrity of the vessel wall, acting as a healthy source of factors to the endothelial cell layer that lines our blood vessels. Conversely, they are poised to respond to signals of vascular damage (e.g. extracellular nucleotides, metabolites, DNA or the collagenous subendothelial matrix) by aggregating and enhancing plasma coagulation.
Individuals with reduced platelet count or function have bleeding tendencies, whereas those with elevated values are at greater risk of heart attacks and stroke. Interindividual variation in platelet parameters like their function, count, and volume is to a large extent inherited and therefore stable over time. The principal aim of our research is to identify genetic sequence variants that regulate these parameters, thus highlighting genes required for platelet production and thereby linked to cardiovascular diseases.
To support this endeavour we have established the Cambridge Platelet Function Cohort (PFC) from the Cambridge BioResource. The platelet function of almost 1,000 volunteers in this cohort has been characterised following activation with adenosine 5′-diphosphate or the collagen mimetic CRP-XL.
The PFC has been used to study the production and signaling activity of glycoprotein VI (GPVI) an important platelet receptor for collagen, and for in silico association studies of other genes identified by the Genome Wide Association Scan for platelet count and volume. This revealed that common sequence variation at Chromosome 7q22.3 exerts not only an effect on the volume of platelets but also on their function.
Platelet RNA samples from donors representing the full range of functional responses have also been applied to whole-genome expression arrays, and analysis of this microarray data identified 63 transcript levels that correlated with variation in platelet functional response. In order to determine whether the corresponding genes were important regulators of thrombus formation. COMMD7 and LRRFIP1 were selected for further study based on the observation that common sequence variants in both loci seemed to be associated with the risk of heart attacks in 4235 cases of premature myocardial infarction compared with 6379 controls.
One bottleneck to understanding the genetic controls of platelet function is the development of suitable testing systems. We are developing new ways of measuring platelet activity by a combination of microfluidics and image processing technology.
Overall we believe that by studying sequence variation in human platelet genes, we will add to knowledge of megakaryopoiesis, platelet formation and the quality of platelet transfusions, as well as to pathways targeted by current or future antiplatelet therapy.
1. Nurnberg ST, Rendon A, Smethurst PA, et al. A GWAS sequence variant for platelet volume marks an alternative DNM3 promoter in megakaryocytes near a MEIS1 binding site. Blood. 2012;120(24):4859-4868.
2. Goodall AH, Burns P, Salles I, et al. Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood. 2010;116(22):4646-4656.
3. Jones CI, Bray S, Garner SF, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood. 2009;114(7):1405-1416.
4. Soranzo N, Rendon A, Gieger C, et al. A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood. 2009;113(16):3831-3837.
Clinical Bioinformatics, Statistical Genetics and Genomics Team
Our team applies statistical and computational methods to discover new genes and molecular mechanisms that control platelet life and function in health and disease. We translate this knowledge into the clinic by developing comprehensive and cost effective DNA tests to improve the diagnosis of inherited bleeding and platelet disorders. Finally we integrate our findings from the gene discovery efforts and from various genome annotation assays (ChIPseq, RNAseq, Riboseq, 4C, HiC, among others) to define the networks of protein-protein interactions and of gene regulation that underpin the lineage commitment and maturation of blood progenitors along the platelet lineage.
Our main projects are:
Thrombogenomics: Streamlining the genetic diagnosis of inherited bleeding and thrombotic disorders under the umbrella of the International Society of Thrombosis and Haemostasis www.thrombogenomics.org.uk.
BRIDGE: Exome and whole genome sequencing to identify the genetic basis of rare diseases with emphasis on cardiovascular disorders bridgestudy.medschl.cam.ac.uk.
Genetics of haematological traits: Discovering new gene functions through genome wide association studies of blood indices and elucidating the molecular mechanisms by which sequence variation alters these traits. Nature 2011, Nature 2012, Blood 2012.
Functional genomics and BLUEPRINT: As part of the BLUEPRINT www.blueprint-epigenome.eu consortium we functionally annotate the genomes of all human blood cells and progenitors. Our group focuses on the platelet lineage and its progenitors.
Integration: This knowledge is integrated to improve our understanding of gene regulation and networks. Wang 2013, NAR; Paul et al 2013 Genome Research.
Gieger et al 2011, Nature
Nürnberg et al 2012, Blood
van der Harst et al 2012, Nature
Wang et al 2013, Nucleic Acid Research
Paul et al 2013, Genome Research
NIHR BioResource for Rare Disease
Our team is responsible for the enrolment of participants with a rare disease; to form a BioResource for Rare Diseases.
A Rare disease is defined as a condition which has an incidence of less than 5 in 10,000 individuals of the UK population, and thus affects ~3% of the population (http://www.raredisease.org.uk/about-rare-diseases.htm). The aims of the BioResource for Rare Diseases are:
(a) to reduce the delay in ascertaining a genetic diagnosis for inherited and acquired genetic disorders (including rare cancers), where the genotype causing phenotype is known, by developing NGST-based diagnostic tests covering NHS diagnostically-important genes; such projects can include translational projects on e.g. a subset of diagnostic genes;
(b) to determine the genetic basis of Inherited Rare Diseases, including rare cancers for which the causative locus has hitherto not been identified, but which have potential wider relevance for the common diseases that are the focus of Biomedical Research Centres/Units (BRC/BRU)-funded translational and experimental medicine research.
Recruitment is via participating BRC/BRU/hospitals with specialist interest in rare diseases, and currently the main focus of our study fall into the themes: infection and immunity, rare cancers, neuroscience and cardiovascular disease. Our active studies are:
Bleeding and Platelet Diseases (BPD) The immediate purpose of this study is to identify the genetic basis of hitherto unresolved bleeding and platelet disorders by exome-sequencing.
Pulmonary Arterial Hypertension (PAH) The discovery of the range of genetic mutations underlying PAH will provide a more complete picture of the cause of this disease and identify rational targets for new drugs. It will also pave the way towards prevention strategies for this disease and of the prediction of prognosis based on a genetic classification of PAH.
Primary Immune Disorders (PID) This study focuses on genetic causes of severe immune disorders, also known as Primary ImmunoDeficiencies with the largest category being CVID, but it may also include the “extreme phenotype” of premature and severe autoimmunity.
Specialist Pathology: Evaluating Exomes in Diagnostics (SPEED) to develop more affordable DNA-based tests for the diagnosis of rare diseases for which the gene is known.
Steroid Resistant Nephrotic Syndrome (SRNS) This study will focus on genetic causes Steroid Resistant Nephrotic Syndrome.
The team spearhead the healthy samples collection for the European consortium, Blueprint (http://www.blueprint-epigenome.eu/) by making use of the NIHR Cambridge Bioresource (http://www.cambridgebioresource.org.uk/) volunteers. The aim of this consortium is to generate reference epigenomes for all the cell types present in the blood as part of the International Human Epigenome Consortium (http://ihec-epigenomes.org/).
Additionally, we apply next generation sequencing methods to further our understanding of megakaryocytes and platelet biology.
Our main projects are:
Comparative Transcription Network Biology: megakaryocyte and neuronal cells make shared usage of several transcription factors and we aim to dissect the mechanisms that lead to different developmental outcomes.
GWAS functional follow-up: recent genome wide association studies of blood indices has led to the discovery of several genes involved in megakaryopoiesis and erythropoiesis. We are using cellular biology and next generation sequencing based techniques to elucidate the function of these genes.
Nuclear Architecture and common variants: in collaboration we are using Hi-C and 4C techniques to map regulatory regions and their target genes in a variety of haemopoietic cell types.
The INTERVAL study is a randomised controlled trial (RCT) in up to 50,000 NHS Blood and Transplant whole-blood donors recruited at the 25 donation centres across England (http://www.blood.co.uk/). Over a period of two years, participants will be randomised to give blood either at their usual donation intervals or more frequently. Current practice is to invite men and women to give whole blood every 12 and 16 weeks, respectively. During INTERVAL men will be randomised to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks. At the end of the study, we will compare the amount of blood donated and assessments of well-being between the different study groups.
The study’s main objectives are to determine:
1. the optimum interval between donations, for men and women, that maximizes blood supply without unacceptably increasing iron deficiency/anaemia and its potential complications;
2. whether blood donation intervals can be tailored to donors on the basis of demographic, haematological, genetic and lifestyle factors.
During the course of the study, additional blood samples will be taken for a full blood count and storage of plasma, serum and DNA. These will be used to measure biomarkers as well as genetic factors. Online questionnaires regarding health, lifestyle and cognitive function will also be collected. A subset of participants will take part in a study of the impact of donation interval on physical activity levels.
The research in the Ouwehand group is funded by the British Heart Foundation, European Commission, The Evelyn Trust, National Institute of Health Research, NHS Blood and Transplant and the Wellcome Trust.